Lilly’s Taltz scrapes win against Humira in psoriatic arthritisEli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been Share XLilly’s Taltz scrapes win against Humira in psoriatic arthritishttps://pharmaphorum.com/news/lillys-taltz-scrapes-win-against-humira-in-psoriatic-arthritis/
Lilly’s migraine drug gets key cluster headache approvalThe FDA has approved Eli Lilly’s Emgality (galcanezumab-gnlm) for the treatment of episodic cluster headache in adults, giving Share XLilly’s migraine drug gets key cluster headache approvalhttps://pharmaphorum.com/news/lillys-migraine-drug-gets-key-cluster-headache-approval/
Lilly cuts $1bn deal for Centrexion’s non-opioid painkillerEli Lilly has signed another bolt-on deal to bulk up its pipeline, this time paying $47.5 million upfront Share XLilly cuts $1bn deal for Centrexion’s non-opioid painkillerhttps://pharmaphorum.com/news/lilly-cuts-1bn-deal-for-centrexions-non-opioid-painkiller/
SMC approves medicines for breast cancer, skin cancer, schizophreniaThe Scottish Medicines Consortium (SMC) has given approvals to Lilly’s breast cancer drug Verzenios, Merck’s Keytruda and Allergan’s Share XSMC approves medicines for breast cancer, skin cancer, schizophreniahttps://pharmaphorum.com/news/smc-approves-medicines-for-breast-cancer-skin-cancer-schizophrenia/
Pfizer/Lilly non-opioid pain drug shows more positive resultsResults from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown that it can Share XPfizer/Lilly non-opioid pain drug shows more positive resultshttps://pharmaphorum.com/news/pfizer-lilly-non-opioid-pain-drug-shows-more-positive-results/
Lilly claims fast FDA review for Emgality in cluster headacheEli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality Share XLilly claims fast FDA review for Emgality in cluster headachehttps://pharmaphorum.com/news/lilly-claims-fast-fda-review-for-emgality-in-cluster-headache/
Lilly to sell generic Humalog insulin at half priceEli Lilly has responded to criticism of high prices for insulin products in the US by launching a Share XLilly to sell generic Humalog insulin at half pricehttps://pharmaphorum.com/news/lilly-to-sell-generic-humalog-insulin-at-half-price/
Lilly’s Verzenios approved by NICENICE has published draft guidance that now recommends Eli Lilly’s breast cancer drug Verzenios for use on the Share XLilly’s Verzenios approved by NICEhttps://pharmaphorum.com/news/lillys-verzenios-approved-nice/
Lilly further boosts cancer pipeline with $8bn Loxo acquisitionIn the second big M&A deal of the year following BMS’s acquisition of Celgene, Eli Lilly has announced Share XLilly further boosts cancer pipeline with $8bn Loxo acquisitionhttps://pharmaphorum.com/news/lilly-further-boosts-cancer-pipeline-with-8bn-loxo-acquisition/
